Maxivent

Quick links to important sections

Maxivent

Method of action: Bronchodilator

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxivent

Quick Facts

Feature Detail
Active Ingredient Doxofylline
Drug Class Xanthine derivative (Bronchodilator)
Primary Use Treatment of obstructive airway diseases
Prescription Required Yes

Maxivent is a brand-name prescription medication used for the treatment of obstructive airway diseases. The active ingredient in Maxivent is doxofylline, a derivative of the xanthine class of drugs, which also includes theophylline. This class of medicine is primarily categorized as a bronchodilator, meaning it helps to widen the airways in the lungs.

Its main indications include the management of symptoms associated with bronchial asthma, chronic obstructive pulmonary disease (COPD), and pulmonary diseases that involve a spastic bronchial component.

Doxofylline works by relaxing the smooth muscles of the bronchi (air passages) in the lungs, which helps improve airflow and relieve difficulty in breathing. Unlike some older xanthine derivatives, doxofylline is specifically noted for having a mechanism of action that may result in fewer cardiovascular side effects compared to theophylline, due to its decreased affinity for certain adenosine receptors. It is an oral tablet formulation and requires a doctor's prescription for purchase.

What side effects are possible with Maxivent?

Possible Side Effects and Safety Information

The officially documented adverse effects for Maxivent (doxofylline) are classified across several System-Organ Classes. These classifications reflect the regulatory framework for communicating the medicine's risk profile.

Adverse effects are often described as being more common at the start of treatment or during dose escalation. Serious adverse reactions are typically associated with elevated drug concentrations.


Documented Adverse Reactions and Safety Constraints

Classification Examples of Officially Listed Effects
Gastrointestinal Nausea, vomiting, and epigastric pain.
Nervous/Psychiatric Headache, irritability, and insomnia.
Cardiac Tachycardia (fast heart rate) and palpitations.

Serious Adverse Reactions and Use Constraints

The regulatory safety profile notes the potential for severe, clinically important reactions, often linked to toxicity, including severe arrhythmias and seizures.

Contraindications define absolute restrictions on use and include hypersensitivity to xanthine derivatives, acute myocardial infarction, and hypotension (low blood pressure).

Special Safety Considerations apply to certain patient groups. Caution is mandated for use in the older adult population and in patients with severe hepatic impairment due to the potential for reduced clearance. The medicine is also officially contraindicated during lactation. The official safety information notes that Maxivent does not pose a risk of tolerance or addiction.

Overdose and Emergency Response

Maxivent Overdose and when to seek help

The official regulatory documentation provides specific guidance on the documented manifestations and required emergency response actions in the event of an overdose.

Feature Official Regulatory Statement
Documented Overdose Presentations Overdose is documented to present with central nervous system manifestations such as seizures, which may be the initial sign of intoxication. Cardiovascular effects include severe arrhythmias and other major cardiac rhythm disturbances. Gastrointestinal symptoms like nausea, vomiting, and bleeding are also noted.
Severe Outcomes & Risks The regulatory profile classifies the intoxication as having the potential for life-threatening outcomes, including severe arrhythmias and severe seizures. Overdosage is documented to have resulted in death.
Emergency Actions Required Administration of Maxivent must be immediately stopped. Urgent action is required: Seek immediate medical attention at the first suspicion of overdose or onset of severe symptoms. Management is strictly symptomatic and supportive.
Antidote Status & Management The official labeling states that no specific antidote is known. Treatment procedures described include establishing and maintaining an adequate airway if seizures occur, and using gastric lavage or activated charcoal for acute overdosage in the absence of seizures.
Population Considerations Patients with conditions that prolong drug plasma levels, such as liver disease or congestive heart failure, have an increased risk of toxicity following overdose.

The regulatory profile strictly defines the overdose risk based on the potential for severe systemic toxicity, necessitating an immediate cessation of the drug and the mandated urgent pursuit of medical care. Because there is no known antidote, official guidance emphasizes prompt supportive measures and symptomatic management to mitigate the life-threatening cardiac and neurological manifestations.

Therapeutic Uses of Maxivent

What Maxivent treats: main uses and benefits

Maxivent is applied in addressing conditions involving episodic or fluctuating manifestations of respiratory distress. These include managing conditions such as chronic obstructive pulmonary disease (COPD) and bronchial asthma. It is used for supportive management in patients with obstructive airway conditions where airflow is suboptimal.

As a bronchodilator, Maxivent is used where additional symptomatic support is needed. It helps ease symptoms related to physical discomfort and heightened physiological activity, such as wheezing and shortness of breath, which interfere with daily functioning. It is commonly used when short-term symptomatic assistance is needed during phases when symptoms become more noticeable.

By easing this systemic burden, Maxivent contributes to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases. It assists with maintaining functional stability.

“Maxivent may help patients cope more steadily with symptom fluctuations by easing distress during difficult episodes.”


Quick Fact: Helps ease Shortness of Breath

Regulatory References

  1. NIH StatPearls overview on Bronchodilators

Eligibility and Restrictions for Use

Who Can and Cannot Use Maxivent?

Maxivent (Doxofylline) eligibility is strictly defined by regulatory authorities based on age, physiological state, and pre-existing medical conditions. Use is generally permitted for adults and children 6 years of age.


Absolute Prohibitions (Contraindications)

Maxivent is contraindicated and must not be used by individuals with a known hypersensitivity to doxofylline or other xanthine derivatives. Absolute contraindications also apply to patients with acute myocardial infarction (AMI) and hypotension. Due to the drug's excretion into breast milk, Maxivent is contraindicated for lactating women.


Restricted or Conditional Use

Use of Maxivent requires caution in patients with certain pre-existing conditions. These include hepatic dysfunction (liver disease) and renal impairment, as drug clearance may be altered. Caution is also necessary for patients with cardiac arrhythmias, hypertension, hyperthyroidism, and a history of peptic ulceration or convulsive disorders.

Special Population Eligibility Status
Children under 6 years Not recommended (Insufficient data)
The Elderly Permitted, but use with caution
Pregnant Women Safety not established (Use only if clearly needed)

What should I know about interactions with other medicines?

Interactions with other medicines and products

Maxivent (doxofylline) has documented interactions that primarily involve changes in the drug’s clearance and formal contraindications with certain compounds.

Interaction Type Interacting Substances/Conditions
Formal Contraindications Other xanthine derivatives (including theophylline and caffeine-containing products); Ephedrine (due to documented toxic synergism).
Reduced Hepatic Clearance Erythromycin, Troleandomycin, Lincomycin, Clindamycin (and other macrolide antibiotics); H2-antagonists (Cimetidine, Ranitidine); Allopurinol; Propranolol; Anti-flu Vaccine.
Increased Clearance Phenytoin and other Anticonvulsants; Cigarette smoking (tobacco).

Interacting Medicinal Products

The regulatory profile mandates that doxofylline must not be administered together with other xanthine derivatives. Co-administration with certain antibiotics, H2-antagonists, and the influenza vaccine is officially stated to decrease the hepatic clearance of doxofylline, potentially causing an increase in the drug's plasma levels. Conversely, concomitant use with anticonvulsants such as Phenytoin and exposure to tobacco smoking are documented to increase clearance, resulting in a shorter half-life.

Population-Specific Notes

The half-life of doxofylline, which dictates the duration and potential severity of interactions, is officially noted to be prolonged in certain populations, including patients with Liver Disease, Congestive Heart Failure, or Chronic Obstructive Lung Disease.

Mechanism of Action

Maxivent (doxofylline) modulates airway physiology through a distinctive pharmacodynamic mechanism involving enzyme inhibition and selective receptor avoidance.

Modulating Airway Smooth Muscle Tone

The core action involves the inhibition of Phosphodiesterase ( PDE) enzymes, particularly PDE2A1, within the airway smooth muscle cells. This inhibition elevates intracellular levels of the second messenger cyclic Adenosine Monophosphate ( cAMP), initiating a cascade that modulates the contractile machinery. The resulting physiological consequence directly reverses the contractile state of the smooth muscle and decreases airflow resistance.

Anti-inflammatory Pathway Modulation

Doxofylline engages the inflammatory gene transcription pathway by promoting the functional restoration of Histone Deacetylase 2 ( HDAC2) activity. HDAC2 helps suppress the expression of various pro-inflammatory mediators. This action contributes to the modulation of chronic airway processes, leading to a reduction in inflammatory gene transcription and tissue hypersensitivity.

Selective Receptor Avoidance

A key mechanistic feature is the drug's negligible affinity for the widespread A1 and A2B Adenosine Receptors. These receptors mediate stimulation of the cardiovascular and central nervous systems. By avoiding antagonism at these sites, the mechanism ensures the targeted respiratory effects are achieved without substantially engaging systemic pathways that mediate non-respiratory organ over-stimulation.

Dosage and Administration Information

How to Use Maxivent

Maxivent is utilized based on parameters that define the route, dose, and frequency of administration. The medication is used for both oral intake, primarily as 400 mg tablets, and for intravenous (IV) administration in a supervised clinical setting for certain requirements.

The standard maintenance regimen for adults is 400 mg per dose, taken two or three times daily (b.i.d. or t.i.d.). This frequency is intended to maintain a stable plasma concentration over the course of long-term chronic management. The oral dose is generally directed to be taken with food.

Regimens are modified for specific patient populations. Older adults (geriatric patients) are advised a reduced dose of 200 mg, two or three times daily. A dose reduction is also generally required for individuals with hepatic or renal impairment due to the potential for drug accumulation.

The IV form is administered by a qualified healthcare professional via a slow intravenous injection over a period of 15 to 20 minutes. As a key procedural constraint, this medication does not act immediately and is restricted from use in the treatment of acute respiratory difficulties.

Recent Clinical Evidence

Research evidence / Overview of Studies for Maxivent


Evidence for use in Chronic Obstructive Pulmonary Disease (COPD)

Maxivent was studied in clinical research exploring the treatment of Chronic Obstructive Pulmonary Disease (COPD), a condition characterized by fluctuating or episodic manifestations. The primary evidence supporting this indication comes from short-term Randomized Controlled Trials (RCTs). These studies, which often compared the medicine to either an inactive treatment (placebo) or an active control group, were conducted in adult patients who met the study's inclusion criteria for COPD severity.

Researchers in these trials primarily monitored objective pulmonary function measures, such as Forced Expiratory Volume in 1 second ( FEV1), which is one of the measures of breathing capacity that research examined. Pooled analyses described a High GRADE (Grading of Recommendations Assessment, Development and Evaluation) of evidence for patterns observed in FEV1 measurements. However, the findings for functional outcomes like the 6-Minute Walk Test were observed to vary across studies. Regarding research limitations, many of the existing trials involved modest sample sizes, and the follow-up durations were limited—often lasting only a few weeks.


Evidence for use in Bronchial Asthma

Maxivent was evaluated in patients with bronchial asthma, a condition involving periods of heightened symptoms and functional limitations. The research base includes double-blind, placebo-controlled RCTs, which are a type of research study often used to assess medicines, as well as systematic reviews. Studies explored the medicine’s use both alone and as an add-on treatment to inhaled corticosteroids.

The studies monitored outcomes reflecting daily functioning and episodic changes. Researchers tracked the frequency of asthma events (exacerbations), patient use of rescue medication, and objective pulmonary function measures like FEV1. Pooled analyses described a High GRADE of evidence for patterns observed in the frequency of asthma events when compared to a placebo. However, some systematic reviews reported no significant differences were observed in the FEV1 measure when Maxivent was evaluated alongside an active xanthine comparator. This data show patterns related to heterogeneity for specific outcomes.


What is Still Uncertain About the Research

Evidence highlights what is known—and what is still uncertain—about the medicine. The primary uncertainty relates to comparative evidence being lacking against the full range of modern therapeutic agents used for both COPD and asthma. Furthermore, because findings were mixed for some objective measures like FEV1 when evaluated alongside an active control, certainty remains low for the comparative performance on these specific outcomes. The research base in the pediatric population (children aged 6 to 18) is also less extensive than the evidence available for adults.

Key Studies & References

  1. Doxofylline for Pediatric Asthma Steps 1–4. Pediatric Asthma: New Role for an Old Drug

Frequently Asked Questions (FAQ)

Common questions about Maxivent (FAQ)


Q: Is Maxivent the same type of medicine as [similar drug name]?

A: Maxivent’s active ingredient, doxofylline, belongs to the xanthine derivative class of medicines, which includes theophylline. Official product information notes a key difference in the drug’s mechanism, as doxofylline has a low affinity for certain receptors that affect the heart and central nervous system. This difference is noted in the mechanism of action.


Q: Is it common for Maxivent to affect [broad organ system, e.g., liver/kidneys]?

A: Regulatory documents advise caution when Maxivent is used by patients with pre-existing liver or kidney impairment. This is because the body’s ability to clear the medicine may be reduced in these conditions. This potential reduction in clearance could lead to higher levels of the drug in the blood, and dose adjustments are generally needed for these populations.


Q: How long does the effect of one dose of Maxivent last?

A: Pharmacokinetic data from official sources indicates that the medicine’s half-life—the time it takes for half of the drug to be eliminated—is typically between 8 to 10 hours during long-term use. This duration guides the recommended dosing schedule of two or three times daily to help maintain stable levels of the medicine.


Q: What common medicines are known to interact with Maxivent?

A: Official documentation identifies certain medicines that can change how your body processes Maxivent. These include specific types of antibiotics (like Erythromycin), stomach acid reducers known as H2-antagonists, some anti-gout medications, and anti-seizure medicines like Phenytoin. Additionally, cigarette smoking is documented to increase the body’s clearance of the medicine.


Q: Can I drink alcohol while taking Maxivent?

A: The official regulatory documentation does not fully establish the interaction with alcohol. However, caution is generally advised, particularly for individuals with liver dysfunction. This caution is based on the possibility that alcohol consumption may exacerbate the drug’s potential side effects.


Q: Is it normal to have a slight headache when first starting Maxivent?

A: Yes, official safety information lists headache as one of the documented Nervous/Psychiatric adverse reactions. These effects are often described in regulatory documents as being more common at the start of treatment or during initial changes in dosage.


Q: Does Maxivent interact with caffeine?

A: Yes, Maxivent is officially contraindicated with other xanthine derivatives and compounds containing caffeine. Therefore, regulatory documents generally recommend limiting the consumption of beverages and food that contain caffeine.


Q: How quickly does Maxivent typically start working?

A: Official documents state that Maxivent does not act immediately and is not indicated for treating sudden, acute respiratory difficulty. Studies show that peak levels in the blood are reached about one hour after an oral dose. A steady, consistent level of the medicine is typically reached in the body after about four days of regular administration.


Q: Does taking Maxivent with food affect how it works?

A: Official prescribing documents direct the oral dose to generally be taken with food. This instruction is usually intended to help manage or reduce common gastrointestinal discomforts, such as nausea or abdominal pain, which are listed as potential side effects of the medicine.


Q: Can Maxivent be used long-term?

A: Yes, the standard recommended dosage is designed for the long-term chronic management of obstructive airway diseases. Furthermore, regulatory safety information confirms that Maxivent does not pose a risk of tolerance or addiction with prolonged use.


Q: Are the research studies on Maxivent mainly focused on adults?

A: The majority of the available research evidence focuses on adults with Chronic Obstructive Pulmonary Disease (COPD) and Bronchial Asthma. Official documents note that the research base available for the pediatric population (children aged 6 to 18) is less extensive compared to the evidence available for adults.


Q: Can Maxivent affect my ability to drive or operate machinery?

A: Official safety information lists potential central nervous system side effects, such as headache and insomnia, which may affect awareness. Individuals are generally advised to be aware of how the medicine affects them before engaging in activities that require full attention, such as driving or operating machinery.


Q: How does Maxivent affect the immune system?

A: Maxivent's mechanism involves an anti-inflammatory pathway modulation through the activity of an enzyme called Histone Deacetylase 2 (HDAC2). This action helps suppress the expression of various pro-inflammatory mediators, contributing to the modulation of chronic airway processes.


Q: Why is Maxivent sometimes prescribed with other medicines?

A: Maxivent has been studied and evaluated for use as an add-on treatment to other primary medications, such as inhaled corticosteroids, in managing conditions like bronchial asthma. Research suggests that using Maxivent in combination may complement the effects of these other medications in controlling symptoms and improving lung function.


Q: Are there any specific dietary restrictions when taking Maxivent?

A: The primary dietary restriction specified in the official documents concerns caffeine. Maxivent is officially contraindicated with other xanthine derivatives and caffeine-containing products due to potential interaction risks.


Q: Can Maxivent affect mood or cause emotional changes?

A: Official safety information lists Irritability as a documented Nervous/Psychiatric adverse reaction. As with any medication that affects the central nervous system, individuals should be aware of any emotional or mood changes and to notify their prescribing healthcare provider if they occur.

How should Maxivent be stored and disposed of?

Maxivent (Doxofylline) must be stored strictly according to regulatory guidelines to ensure stability.

Storage Requirements

Condition Requirement
Temperature Store at a temperature not exceeding 30°C.
Protection Keep the tablets in the original blister pack to protect them from moisture and environmental factors.
Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Maxivent should be disposed of via a local drug take-back program if available. If a take-back program is not accessible, tablets must be removed from the packaging, mixed with an undesirable substance (such as used coffee grounds or dirt), and sealed in a container before being thrown in the household trash. Do not flush the medicine down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Maxivent found in:

A-Z Index: